Ascendia

  MARKET NEWS

Eli Lilly Makes $2.8 Billion Neuropsychiatry Acquisition
CellCarta Launches Digital Pathology and AI Consortium to Accelerate Platform-Agnostic Biomarker Innovation Across Drug Development
Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector

  EXPERT CONTENT & RESOURCES

Nina Bauer

Why NAMs Took Decades to Arrive – and Why iPSCs are Making Them Possible

When US and European regulators acted in recent years to support the use of animal model alternatives for drug development, reactions were mixed. There is broad acknowledgement regarding the limitations of animal-based disease models and their inability to fully recapitulate human biological complexity, contributing to a high clinical failure rate, and so there was true excitement for the possibilities.

eBook: Understanding the Foundation of LNP Formulation Success

eBook: Understanding the Foundation of LNP Formulation Success

Lipid nanoparticles (LNPs) are one of the most significant advances in drug delivery in decades. But developing successful LNP formulations demands deep knowledge of their key building blocks: Lipids.

Avoiding Recalls: How to Ensure Sterility in Ophthalmic Products

Avoiding Recalls: How to Ensure Sterility in Ophthalmic Products

In the wake of several high-profile eye drop recalls, we look at the challenges of achieving sterility in ophthalmic products, the consequences of failing to do so, and how AbbVie Contract Manufacturing ensures product sterility and safety.

  FEATURED EDITORIAL

Drug Development & Delivery

  EXPERT INSIGHTS VIDEOS

What Contamination Control Strategy (CCS) Means for Customer Confidence in Sterile Manufacturing

What Contamination Control Strategy (CCS) Means for Customer Confidence in Sterile Manufacturing

  COMPANY PROFILE

Mitsubishi Gas Chemical (MGC) is a leading company in the field of oxygen barrier and absorbing polymers. Based on these technologies and experiences, MGC launched new multilayer plastic vial named OXYCAPT™ in 2019. It has achieved an excellent oxygen, carbon dioxide, ultraviolet (UV) barrier, high water vapor barrier, very low extractables, high pH stability, low protein adsorption, high transparency, high break resistance, easier disposability, lighter weight, etc.

Click here for more.

 

HERMES PHARMA is the leading expert in developing and manufacturing user-friendly oral dosage forms. As a CDMO, we offer customized services along the entire pharmaceutical value chain, from new product development and formulation to manufacturing and regulatory support. For more than 40 years, healthcare companies around the globe have worked with HERMES PHARMA to expand their product lines and grow their brands.

Our sister company HERMES Arzneimittel has a rich portfolio of OTC brands and a long history in pharmaceutical excellence. So, we truly understand the challenges of our customers and can support them on their way to market success.

Click here for more.

  WHITEPAPERS & WEBINARS

WEBINAR ON DEMAND: Why early matters: Data-driven strategies to de-risk OSD development

WEBINAR ON DEMAND: Why early matters: Data-driven strategies to de-risk OSD development

Late-stage surprises continue to drive cost, delay, and challenges in oral solid dosage (OSD) development—especially for complex, poorly soluble molecules. Too often, formulation and manufacturability risks surface only after significant time and investment.

In a recent panel discussion, GlobalData’s Director …

WHITEPAPER - An Introduction to PLG Polymers for Long‑Acting Drug Delivery

WHITEPAPER - An Introduction to PLG Polymers for Long‑Acting Drug Delivery

Bioabsorbable poly(lactide-co‑glycolide) (PLG) polymers and poly(lactic acid-co-glycolic acid) (PLGA) have become an essential part of modern healthcare. Over the past five decades, these polymers have transformed how medicines are delivered – enabling long-acting injectables, implants, and localized drug‑delivery products …

WHITEPAPER - From Service Provider to Strategic Partner

WHITEPAPER - From Service Provider to Strategic Partner

By: Tom Sellig, CEO, Adare Pharma Solutions

As drug development grows more complex and timelines compress, sponsors require CDMO relationships built on integration, flexibility, and shared accountability. The relationship between pharmaceutical sponsors and their CDMO partners has undergone a fundamental …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

July 29 – Drug Delivery
August 5 – Injection Devices
August 12 – Lyophilization Manufacturing
August 19 – Excipients